Drug Trial Radar · NCT05298423
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
610
Actual
Start
May 3, 2022
Primary completion
Jun 15, 2026
Study completion Jun 15, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
pembrolizumab/vibostolimabBiological
Administered as an intravenous (IV) infusion
durvalumabBiological
Administered as an IV infusion
cisplatinDrug
Cisplatin 75 mg/m\^2 administered as an IV infusion in combination with pemetrexed on Day 1 of Cycles 1-3 for non-squamous histology only; In combination with etoposide, cisplatin 50 mg/m\^2 is administered on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3
pemetrexedDrug
Pemetrexed 500 mg/m\^2 administered as an IV infusion on Day 1 of Cycles 1-3 for non-squamous histology only
etoposideDrug
Etoposide 50 mg/m\^2 is administered as an IV infusion on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3;
carboplatinDrug
Carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
paclitaxelDrug
Paclitaxel 200 mg/m\^2 on Day 1 of Cycle 1 and 45 mg/m\^2 on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
thoracic radiotherapyRadiation
60 Gray \[Gy\] in 2 Gy fractions for 30 days total administered as an external beam radiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 48 months
- Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)Time frame: Up to approximately 48 months
Locations
160 sites in 25 countries. Site status is shown where the registry gives one.
VA Long Beach Healthcare System ( Site 2831)
Long Beach, California
VA West Los Angeles Medical Center ( Site 2808)
Los Angeles, California
Millennium Oncology Research Clinic ( Site 2801)
Hollywood, Florida
Mid Florida Hematology and Oncology Center ( Site 2800)
Orange City, Florida
Moffitt Cancer Center ( Site 2818)
Tampa, Florida
University of Chicago Medical Center ( Site 2828)
Chicago, Illinois
Franciscan St. Francis Health ( Site 2812)
Indianapolis, Indiana
MFSMC-HJWCI ( Site 2804)
Baltimore, Maryland
Boston Medical Center ( Site 2829)
Boston, Massachusetts
University of Massachusetts Chan Medical School ( Site 2815)
Worcester, Massachusetts
University of Missouri Hospital ( Site 2839)
Columbia, Missouri
Cox Medical Center North-Cox Medical Center/Hulston Cancer Center/ Radiation Oncology ( Site 2837)
Springfield, Missouri
Rutgers Cancer Institute of New Jersey ( Site 2805)
New Brunswick, New Jersey
Icahn School of Medicine at Mount Sinai ( Site 2821)
New York, New York
White Plains Hospital ( Site 2835)
White Plains, New York
Kaiser Permanente Northwest-Central Interstate--Oncology ( Site 2816)
Portland, Oregon
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 2827)
Lancaster, Pennsylvania
Thomas Jefferson University - Clinical Research Institute ( Site 2813)
Philadelphia, Pennsylvania
Millennium Research & Clinical Development ( Site 2811)
Houston, Texas
Central Texas Veterans health care-Oncology & Hematology ( Site 2819)
Temple, Texas
MultiCare Health System ( Site 2817)
Tacoma, Washington
Clinica Adventista Belgrano ( Site 3601)
Caba., Buenos Aires F.D., Argentina
Instituto Médico Río Cuarto ( Site 3600)
Río Cuarto, Córdoba Province, Argentina
Sanatorio Parque ( Site 3602)
Rosario, Santa Fe Province, Argentina
Canberra Hospital ( Site 0010)
Canberra, Australian Capital Territory, Australia
Icon Cancer Centre Hobart ( Site 0003)
Hobart, Tasmania, Australia
Ballarat Health Services-Medical Oncology ( Site 0002)
Ballarat Central, Victoria, Australia
Frankston Hospital-Oncology and Haematology ( Site 0009)
Frankston, Victoria, Australia
St Vincent's Hospital-Oncology Clinical Trials ( Site 0005)
Melbourne, Victoria, Australia
Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 0105)
Rio de Janeiro, Brazil
A. C. Camargo Cancer Center-CAPEC ( Site 0102)
São Paulo, Brazil
Hospital Nossa Senhora da Conceição ( Site 0111)
Porto Alegre, Rio Grande do Sul, Brazil
James Lind Centro de Investigacion del Cancer ( Site 0202)
Temuco, Araucania, Chile
Biocenter ( Site 0208)
Concepción, Biobio, Chile
FALP-UIDO ( Site 0205)
Santiago, Region M. de Santiago, Chile
Centro de Oncología de Precisión ( Site 0209)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0200)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 0203)
Viña del Mar, Valparaiso, Chile
Beijing Cancer hospital-intrathoratic deparmtment II ( Site 0328)
Beijing, Beijing Municipality, China
Beijing Cancer hospital-Oncology Radiotherapy Department ( Site 0309)
Beijing, Beijing Municipality, China
Showing 40 of 160 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.